(Q58204787)

English

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

scholarly article by Takao Koike et al published 13 October 2011 in Modern Rheumatology

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients (English)

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1

object named as

Takao Koike

0 references

Hisashi Yamanaka

7

object named as

Hisashi Yamanaka

0 references

author name string

Masayoshi Harigai

2

0 references

Naoki Ishiguro

3

0 references

Shigeko Inokuma

4

0 references

Shuji Takei

5

0 references

Tsutomu Takeuchi

6

0 references

Yoshiya Tanaka

8

0 references

publication date

13 October 2011

0 references

Modern Rheumatology

0 references

22

0 references

4

0 references

498-508

0 references

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

The Japanese experience with biologic therapies for rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Predictors of infection in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Initiation of rheumatoid arthritis treatments and the risk of serious infections

1 reference

https://api.crossref.org/works/10.1007%2FS10165-011-0541-5

21 January 2018

Identifiers

10.1007/S10165-011-0541-5

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58204787&oldid=2213776878"